spacer
home > epc > Winter 2015
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2015

   
Text
PDF
bullet
Marketplace & Business
CRO Growth

Deal Me In


Contract research continues to thrive as CROs strengthen their R&D services and sponsors tighten their budgets. Growth is surging this year and predicted to at least the end of the decade, driven by the big players and market consolidation. EPC has more.
 
view
download pdf
bullet
Legal & Regulatory
Patent Protection

Optional Extras


It is uncertain times for patent portfolios in Europe, with pharma companies large and small working out whether to opt in or out of the Unifi ed Patent Court system, coming in 2017. The risks, rewards and crucially costs of the new regime must all be weighed up, says Paul Harris at Pillsbury Law.
 
view
download pdf
bullet
Science & Innovation
Business Models

Eco Friendly

A new ecosystem model is rapidly evolving in pharma and life sciences. Heather Fraser at IBM explains how it will require a level of collaboration the industry has not engaged in before, transcending boundaries and stimulating a growth in innovation.
 
view
download pdf
bullet
DATA MANAGEMENT
Q&A: Investigator Site Data

Joint Ventures


Through collaborative efforts such as the Shared Investigator Platform, biopharma partners are working to lessen administrative burdens for investigators and enhance the patient experience. Jackie Kent of Eli Lilly and TransCelerate talks to EPC.
 
view
download pdf
bullet
Risk Management
Pharmacovigilance

Progress Report


EPC offers a run-down of specific measures being implemented by the EMA to maximise the efficiency of the EudraVigilance safety reporting system for adverse events, following a significant decline in signals in 2014.
 
view
download pdf

Research and Development
Preclinical Development

Non-Clinics: Progression

Exploring the changing face of non-clinical development, Envigo's Lee Coney looks at the intricacies of investigating the safety and pharmacology of biologic drugs before they enter clinical trials, and the essential role of CRO players.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

New awareness campaign aims to help organisations prepare for GS1


More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

Industry Events

ISPPP_2017

19-21 July 2017, Philadelphia, PA, USA

Mark your calendar to attend the premier meeting on state-of-the-art separation, analysis, and characterization methods, much of which is based on HPLC/UHPLC/Mass Spectrometry.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement